In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

The Philadelphia Citizen is recognizing CHOP doctors Alexis Thompson and Dr. Stephan Grupp with the 'Disruptors of the Year' ...

Nearly a year after new sickle cell gene therapies were approved, CNBC's Bertha Coombs reports a small number of patients are ...

A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.

At least 29 recruits have died during basic training at law enforcement academies nationwide in the last decade.

On a family vacation, 14-year-old Jaden Hartley discovered he needed a heart transplant after experiencing this symptom. Now ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Simmie White is taking control of her own story. The six-year-old girl and her mother want others to understand more about ...

As treatment and care continues to evolve, we must ensure that people living with this disease are able to advocate for ...

“We still have a serious challenge with sickle cell disease, which contributes to 20% of under-five mortality every year.

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.